Is It Really AMD, or Pachychoroid Neovasculopathy?
Wet AMD and Pachychoroid Neovasculopathy at a Glance
Some changes should not wait for your next routine visit. Call your eye doctor the same day if you notice any of these:
- Sudden vision loss in one eye or in both eyes.
- A new dark or gray spot in the middle of your sight.
- Straight lines that look bent, wavy, or broken.
- A quick drop in how clearly you see faces or read words.
- A new curtain or shadow over part of your sight.
These signs can mean new leaking vessels have grown under the retina. That is treatable. Finding active leaking vessels early and treating them promptly leads to better vision results1. Many people who are seen quickly keep useful central vision. So make the call now, then take a breath while you wait.
Both conditions end in the same place. New, fragile blood vessels grow under the center of your retina and leak fluid or blood, which blurs and distorts your central vision. They start differently. Wet age-related macular degeneration is the advanced, less common form of AMD, an aging disease of the macula in which abnormal vessels drive faster vision loss2. Pachychoroid neovasculopathy takes a different route to the same leak: vessels grow over a patch of unusually thick choroid, the vessel layer beneath the retina, in an eye without the usual drusen deposits of AMD3.
The label is not just paperwork. It shapes which treatment your retina specialist reaches for, how often you need it, and what a realistic outlook looks like. In one hospital series of patients newly diagnosed with a leaking macula, 35 of 139 were graded as having pachychoroid disease rather than AMD, and 19 of 123 people whose charts already said AMD were regraded as pachychoroid disease4. One series cannot tell you how often this happens everywhere, but asking your doctor which one they think you have, and how they decided, is a fair question.
If you have new distortion or blur in your central vision, the next step is a retina specialist and a scan of the back of your eye, not a wait-and-see period at home. Bring a list of your medicines, especially any steroid pills, creams, inhalers, or injections, since steroid exposure matters for pachychoroid disease. Bring someone who can drive you, because your eyes will be dilated.
What Wet AMD Is, and What Pachychoroid Neovasculopathy Is
AMD is an aging disease of the macula, the central patch of retina that handles sharp detail. It blurs central vision, about 11 million people in the United States have it, and risk rises after about age 55, with family history and smoking adding to that risk2. Side vision is generally preserved5, which is why people with advanced AMD usually still move around a room but struggle with faces and print. The dry form makes up roughly 8 of every 10 AMD cases and involves a thinning macula with yellow drusen deposits underneath5. Drusen are the fingerprint of AMD, and their presence or absence carries much of this question.
Wet AMD, also called neovascular AMD, is the stage where new vessels enter the picture. New abnormal blood vessels grow under the retina and can leak blood or other fluid, which scars the macula and takes vision down faster than the dry form does5. The word 'wet' refers to that fluid, not to watery eyes. Injections of anti-VEGF medicine into the eye are the first-line treatment1, and they quiet the signal telling those vessels to grow and leak.
Pachychoroid neovasculopathy, often shortened to PNV, is a newer name for a pattern retina doctors kept seeing in younger patients. Pachychoroid means thick choroid (clinical: an abnormally thickened choroid, the vessel layer that feeds the retina from behind). PNV is a type 1 macular neovascularization growing over a local patch of thickened choroid with widened large choroidal vessels and a thinned inner choroidal layer, and VEGF levels measured inside the eye are lower than in neovascular AMD3. In plainer terms, the choroid underneath is congested, the layer above it is worn thin, and vessels push into a space they should not occupy.
Some people with PNV have a history of central serous chorioretinopathy, or CSC. CSC is fluid collecting under the retina, most often in people aged 35 to 55 and more often in men, with reported associations including corticosteroid use, sleep apnea, and high stress; most episodes settle within about three months without treatment, and roughly half of people have it come back6. The pachychoroid spectrum links CSC, pachychoroid neovasculopathy, and polypoidal choroidal vasculopathy, and PNV can progress into the polypoidal form3. If you were told years ago that you had fluid under your retina, mention it.
How the Two Conditions Compare, Side by Side
Age is the single most useful clue, though it is a tendency rather than a rule. People with pachychoroid disease are typically diagnosed younger, as the figures below show.
| Feature | Wet AMD | Pachychoroid neovasculopathy |
|---|---|---|
| Average age in the series cited below | About 81 years | About 67 to 69 years |
| Sex pattern | Affects men and women | Men more often than women |
| Past fluid episodes | Not typical | Sometimes a history of central serous fluid |
In the hospital series above, the pachychoroid group averaged 67.0 years while the AMD group averaged 80.7 years4. In a separate series of 99 eyes with PNV, average age was 69.3 years and 79 of 99 patients were men7. A younger patient with a leaking macula is a reason to look harder at the choroid.
The imaging differences are where the diagnosis is made. Two features carry most of the weight: whether drusen are present, and how thick the choroid is underneath.
| Imaging feature | Wet AMD | Pachychoroid neovasculopathy |
|---|---|---|
| Drusen under the retina | The hallmark deposit of AMD | Absent, or only small hard ones |
| Choroid thickness under the fovea | Thinner on average | Thicker on average |
| Large choroidal vessels | Not dilated | Widened, with a thinned layer above |
In a series where 43 of 100 eyes were graded as pachychoroid neovasculopathy, drusen were found in 0 of those 43 eyes but in 11 of the 57 other eyes, and the choroid under the fovea averaged 298 micrometers in the pachychoroid group against 228 micrometers in the rest8. A separate PNV series measured an average of 307.6 micrometers7. Drusen counts differ with how they are graded, these are averages, and individual eyes overlap, which is why the distinction takes more than one scan.
Symptoms alone will not separate the two, which is worth knowing before you try to work it out at home. Both typically cause a blur or gray patch in the center of your sight, wavy straight lines, and difficulty reading in ordinary light. The Academy advises calling an ophthalmologist right away if lines on an Amsler grid look wavy, blurry, or dim5. Both can also start quietly in one eye while the other compensates, which is why checking one eye at a time matters.
Put simply: an older patient with drusen in both eyes and a thin choroid fits wet AMD, while a middle-aged patient with no drusen, a thick choroid, and perhaps a past episode of fluid fits pachychoroid neovasculopathy. Plenty of people sit between those descriptions. Being in the middle is not a failed workup, and it does not stall your care. Anti-VEGF injection is the first-line treatment for neovascular AMD1, and it is also the usual starting point while the classification is still being sorted out.
How Your Eye Doctor Tells the Two Apart
The workhorse test is optical coherence tomography, or OCT, a light-based scan that builds a cross-section of your retina without touching your eye. Diagnosis of macular degeneration uses a dilated eye exam, OCT imaging, and fluorescein angiography, in which a yellow dye is injected into a vein so leaking vessels show up5. For this question, your doctor uses a setting that reaches deeper than usual so the full choroid is measurable. They look for two things at once: drusen above, and choroidal thickness and vessel width below. The scan does not hurt and takes minutes per eye.
When the OCT is ambiguous, dye imaging usually settles it. Indocyanine green angiography uses a dye that shows the choroid rather than the retina, so it can reveal congested, leaky choroidal vessels and any polypoidal lesions beneath. In a series of 99 PNV eyes, leaky choroidal vessels on this test were seen in about 57 of every 100 eyes, and polypoidal lesions in about 56 of every 100 eyes7. OCT angiography, which maps blood flow without dye, is often added to show the vessel network itself.
Mix-ups happen because the two can look nearly identical at the surface: a shallow, irregular lifting of the pigment layer with fluid above it. In one hospital-based series, 19 of 123 patients whose records recorded AMD were regraded as pachychoroid disease once the choroid was assessed carefully4. That is one centre's experience, not a national rate, and it is a reason for a second look rather than a reason to distrust your doctor.
How Treatment Differs Once the Diagnosis Is Clear
Both conditions are usually treated first with anti-VEGF injections, medicines delivered into the eye through a fine needle after numbing drops. Intravitreal anti-VEGF injection is the first-line treatment for neovascular AMD, and early detection with prompt treatment improves visual outcomes1. Aflibercept and ranibizumab are two of the medicines used. Most people describe the injection as pressure rather than pain. What differs between the two conditions is usually not the first injection, but how many follow it.
Photodynamic therapy, or PDT, uses a light-activated drug called verteporfin plus a low-energy laser to quiet overactive vessels. It is used more in pachychoroid disease than in wet AMD, often alongside an injection4. The FDA-approved uses of verteporfin (Visudyne) cover certain kinds of vessel growth in AMD, pathologic myopia, and ocular histoplasmosis, and pachychoroid neovasculopathy is not among them9, so this is an off-label use your doctor should discuss. In a multicenter series of 42 previously untreated PNV eyes given one combined session, 32 of 42 eyes needed no further treatment over 12 months10. That is a small retrospective series, not a head-to-head trial.
This is where the distinction becomes practical. In the comparison series, eyes with pachychoroid neovasculopathy had a dry macula after the loading injections in about 91 of every 100 eyes against about 59 of every 100 in the other group, needed fewer injections over two years (an average of 11.0 against 13.4), and reached longer gaps between treatments by two years (an average of 12.1 against 8.4 weeks)8. Those are group averages from one centre, and your own schedule will be set by how your eye responds. Still, an accurate label can mean fewer trips to the clinic.
Risks, Complications, and a Realistic Outlook
Left alone, leaking vessels under the macula can scar it, and scarred vision does not come back. In wet AMD, new abnormal vessels leak blood or fluid and scar the macula, and vision worsens faster than in the dry form5. That is the honest risk, and it is also why the news is better than it sounds: this is a retinal problem with an effective, widely available treatment, and early detection with prompt treatment improves visual outcomes1. The gap between a good result and a poor one is often measured in how quickly someone acted.
As groups, people with pachychoroid neovasculopathy tend to do somewhat better, though both vary widely. In the hospital series, the pachychoroid group had better average vision at one year than the AMD group (0.34 against 0.59 on the logMAR scale, where a lower score is better)4. Part of that gap is likely age and starting vision rather than the condition itself. Pachychoroid neovasculopathy can also progress to polypoidal choroidal vasculopathy3, which is a reason for ongoing follow-up even when things look calm. Better on average does not mean untroubled.
Every number on this page describes a group of patients, most from retrospective studies at specialist centres, and none describes you. Your outlook depends on how much vision you started with, whether there is bleeding or scarring already, and how your eye responds to early treatment. No page and no scan can promise you a particular result. What your retina specialist can give you, after seeing your images and your early response, is a realistic range and a plan.
When to Call, and Who Should Be Watching Your Eyes
Certain changes deserve a phone call on the day you notice them. New distortion of straight lines, a new gray or dark patch in your central vision, a sudden drop in sharpness, or a new shadow across your sight all belong in that group. The Academy advises calling an ophthalmologist right away if lines on an Amsler grid look wavy, blurry, or dim5. If you are already having injections, symptoms suggesting an infection inside the eye or a detached retina need prompt evaluation too1. Reaching out early usually means a small adjustment rather than a big problem.
Home monitoring is useful here, because both conditions can shift quietly. Use an Amsler grid, a square of graph paper with a central dot, at the same distance in good light each day. Cover one eye, look at the dot, and notice whether any lines bend, blur, or vanish, then repeat with the other eye. Doing it one eye at a time is the step people skip, and it is the one that matters, since a good eye masks a changing one.
A leaking macula is retina specialist territory. That is an ophthalmologist with extra training in the retina and choroid, and they give the injections, read the deeper scans, and decide whether photodynamic therapy has a role. Your optometrist or general ophthalmologist often spots the problem first and starts the referral, then stays involved for routine care. If your diagnosis is uncertain, or your treatment does not seem to be settling the fluid, asking about a second opinion is a normal step.
Questions People Ask About AMD and Pachychoroid Disease
Yes, and this is part of why the distinction can be hard. An older person can have drusen from AMD in both eyes and also have a thick, congested choroid. When features overlap, retina specialists usually describe which pattern dominates rather than forcing a single label, and they treat the active leak in front of them. Ask your doctor which features they see in your scans and which one they think is driving the problem. That answer is often more useful than the chart label.
It is possible but less typical, and that is exactly where pachychoroid neovasculopathy deserves consideration. AMD risk climbs after about age 552, while pachychoroid disease is often found in people in their forties, fifties, and sixties. If you are on the younger side and have been told you have wet AMD, it is reasonable to ask whether your choroid was measured and a pachychoroid pattern ruled out. Mention any past episode of fluid under the retina.
Corticosteroid use is a reported risk factor for central serous chorioretinopathy6, which sits on the same spectrum as pachychoroid neovasculopathy. That includes steroid tablets, injections, strong skin creams, and some inhalers, not only high-dose courses. This does not mean steroids caused your condition, and it does not mean you should stop a prescribed medicine on your own. Tell both your eye doctor and the prescriber, so they can weigh whether the dose or route can be adjusted safely.
Complete blindness is not the usual course of either condition. Both affect central vision while side vision is generally preserved5, so people who lose central detail still keep the vision they use to move around. Treatment aims to stop the leaking before scarring sets in, and starting early gives the best chance of holding onto reading vision. Nobody can promise you a particular result, but your specialist can give you a realistic picture once they see how your own eye responds.
More Questions About Getting the Right Diagnosis
Ask three concrete things: whether your choroidal thickness was measured on a deep OCT scan, whether drusen are present in either eye, and whether indocyanine green angiography was done or considered. Those answers cover most of what separates the two conditions. If your doctor has weighed all three and still says AMD, that is a well-founded answer. If one has not been looked at, asking for it is a reasonable request, not a challenge.
The supplement formula studied in this field was tested in age-related macular degeneration and is offered for intermediate AMD2, not for pachychoroid disease, so there is no good evidence it changes the course of pachychoroid neovasculopathy. If you were told to take it, that advice was probably based on an AMD diagnosis. Ask your retina specialist whether it still makes sense given your diagnosis, and do not start or stop it based on a web page alone.
Yes, keep watching it, because both conditions can involve the second eye later. Check each eye separately with an Amsler grid, keep your follow-up visits even when nothing feels wrong, and report any new distortion promptly rather than assuming it is your glasses. Smoking raises the risk of AMD2, so stopping is worth discussing. Your specialist usually scans both eyes at your visits, so the fellow eye is being watched even when it is not being treated.
- Which condition do you think I have, and which imaging findings led you there?
- Was my choroidal thickness measured, and what was it?
- Do I have drusen in either eye?
- Would indocyanine green angiography add anything useful in my case?
- What is the plan if my macula does not dry out after the first few injections?
- Is photodynamic therapy an option for me, and what would it change?
- What specific changes should make me call you the same day?
- American Academy of Ophthalmology, Preferred Practice Pattern (2024). Age-Related Macular Degeneration Preferred Practice Pattern (2024, updated 2026).
- National Eye Institute (NEI), National Institutes of Health (2021). Age-Related Macular Degeneration (AMD).
- American Academy of Ophthalmology, EyeWiki (2024). Pachychoroid Neovasculopathy (PNV).
- Scientific Reports (peer-reviewed) (2020). Rate of misdiagnosis and clinical usefulness of the correct diagnosis in exudative neovascular maculopathy secondary to AMD versus pachychoroid disease.
- American Academy of Ophthalmology, EyeSmart (2025). What Is Macular Degeneration?.
- American Academy of Ophthalmology, EyeSmart (2025). What Is Central Serous Chorioretinopathy?.
- Scientific Reports (peer-reviewed), Tagawa and colleagues (2020). Characteristics of pachychoroid neovasculopathy.
- Scientific Reports (peer-reviewed), 13:7379 (2023). Pachychoroid neovasculopathy has clinical properties that differ from conventional neovascular age-related macular degeneration.
- U.S. Food and Drug Administration (2023). Visudyne (verteporfin for injection) prescribing information, NDA 021119.
- PLOS ONE (peer-reviewed), multicenter retrospective series (2021). Photodynamic therapy combined with anti-vascular endothelial growth factor therapy for pachychoroid neovasculopathy.